In this context Yu et al. examined the effect of the dual PI3K/mTOR inhibitor dactolisib (NVP-BEZ235) in patient-derived and in radioresistant oral squamous cell carcinoma cells in vitro and in an in vivo tumor model. This evidence concerns the gene MTOR and neoplasm.